Drug intelligence / Profile preview

BimaGard

Development stage: Unknown
Lead developer: Bimeda
Modality: Small Molecules
Administration: Oral

Overview

BimaGard is a veterinary antibiotic liquid concentrate containing 12.5% tiamulin hydrogen fumarate. It is a pleuromutilin antibiotic indicated for the treatment of swine dysentery associated with Brachyspira hyodysenteriae and swine pneumonia caused by Actinobacillus pleuropneumoniae. Developed and manufactured by Bimeda, Inc., BimaGard is an FDA-approved generic version of Denagard. The drug works by binding to the 50S subunit of the bacterial ribosome, specifically at the peptidyl transferase center, thereby inhibiting bacterial protein synthesis in susceptible pathogens. It is administered to swine via drinking water for five consecutive days.

Brand names: BimaGard
Other names: BimaGard 12.5%

Targets

PTC (50S ribosomal peptidyl transferase center)

Beyond the preview

Go deeper on BimaGard.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BimaGard.

Explore the full profile